biomarker validation
Cofactor Quickly Moving Immunotherapy Predictive Test to Market With Data From Intermountain Spinout
Premium
Culmination Bio's 4.5 million biospecimens and longitudinal omics and clinical data may help Cofactor rapidly advance the OncoPrism assay into multiple cancer types.
The company is currently testing the drug in a trial, which it hopes will show benefits in a biomarker-defined subset of patients with treatment-resistant depression.
Function Oncology Launches With $28M, Seeks to Transform Precision Cancer Therapy With CRISPR
Premium
The firm unveiled early validation data for its CRISPR-based functional genomics platform, which it hopes to commercialize as another tool doctors can use to individualize cancer care.
Immune Signatures Outperform TILs for HER2-Positive Breast Cancer Prognoses
Immune-related gene expression signatures tracked more closely with treatment response and outcomes than tumor-infiltrating lymphocytes in early-stage HER2-positive breast cancer.
Higher TIL Levels in Residual Disease May Predict Worse Survival in HER2-Positive Breast Cancer
Premium
Researchers homed in on a composite biomarker to assess overall survival for HER2-positive breast cancer patients with residual disease after neoadjuvant therapy.